Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 21;19(6):1846–1860. doi: 10.7150/ijbs.79654

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Niraparib combined with Entinostat suppressed HRD ovarian tumor growth in vivo. (A) Diagram illustrated the processes of animal experiment. (B) The tumor burden was evaluated by weighing weekly after treatment. Data were presented by mean value of 5 mice per group ± standard error. (C) Bar plot showed ascites volume (ml) by the end of experiment in four subgroups. (D)The picture showed the bloody degree of ascites in four subgroups. A volume of 6ml ascites in each subgroup was collected for examination. (E) The tumor burden was evaluated by quantifying total flux with PE Living Image software. Data were presented by mean value of 5 mice per group ± standard error. (F) Bioluminescence of C57BL/6j mice after inoculation of Trp53^-/-Brca2^-/--ID8-Luc cells. (G) The tumor burden was evaluated by weighing weekly after treatment. Data were presented by mean value of 5 mice per group ± standard error. (H) Bar plot showed ascites volume (ml) by the end of experiment in four subgroups. Nira: Niraparib, Enti: Entinostat.